Molecular cloning and sequence analysis of the cDNA for ancrod
, a thrombin-like enzyme from the venom of Calloselasma rhodostoma.
Eliminating fibrin deposits via the snake venom ancrod
following muscle damage resulted in increased muscle repair and regeneration (22).
Randomized controlled trials of acute reduction in plasma fibrinogen with a defibrinating snake venom enzyme, ancrod
, have shown reductions in the risk for venous thromboembolism in surgical and stroke patients and a reduction in cerebral infarct size in acute ischemic stroke (6); however, the benefit of the latter effect was outweighed by an increased risk of intracranial bleeding.
Heparine bagli trombositopeni gelisen hastalarda KPB sirasinda antikoagulasyon icin danaparoid, ancrod
ve recombinant hirudin tercih edilebilir.
These include ancrod
, derived from the Malaysian pit viper's venom, and desmoteplase, derived from the vampire bat's saliva.
) is currently being studied in two Phase III global trials known as Ancrod
Stroke Program I (ASP-I) and Ancrod
Stroke Program II (ASP-II).
(NTI) (NASDAQ:NTII) has signed agreements with Nordmark Arzneimittel GmbH & Co KG (Nordmark) and Baxter Pharmaceutical Solutions, LLC (Baxter) to manufacture, fill and package Viprinex(TM) (ancrod
) for NTI's Phase III clinical trials in acute ischemic stroke.
Other antithrombotic agents being evaluated include oral heparins; other direct thrombin inhibitors like lepirudin, bivalirudin, and argatroban; defibrinating agents such as ancrod
; anti-inflammatory agents such as P-selectin inhibitors; Factor VIIa inhibitors; tissue factor pathway inhibitor; and activated protein C.
As part of the transaction, NTI has acquired the exclusive worldwide rights to Viprinex(TM) (ancrod
), a late-stage perfusion therapy for use in the treatment of acute ischemic stroke.
Trials in the US found that 40 per cent of patients who took Ancrod
, the drug purified from the venom, recovered their physical and mental ability.
Anticoagulant therapy with vitamin K antagonists should be initiated 3 or 5 days after heparin suspension, when platelet counts are increasing, but preferably before resolution of the thrombocytopenia to avoid potential worsening of the thrombotic picture.[6,97] However, heparin discontinuation alone and substitution with dicumaroids do not prevent the onset of severe thrombotic complications in nearly 50% of affected patients.[8,34,97] On the basis of these disappointing results, new approaches have been proposed that have included the use of LMWH, heparinoids, anticoagulating agents such as ancrod
, prostaglandin (Iloprost), antiplatelet drugs, and thrombin inhibitors (argatroban and hirudin).